Guidance
9 Related NICE guidance
Published
-
Neutropenic sepsis: prevention and management of neutropenic sepsis in cancer patients (2012) NICE guideline CG151
-
Colorectal cancer (2012) NICE quality standard 20
-
Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (2012) NICE technology appraisal guidance 242
-
Colorectal cancer: the diagnosis and management of colorectal cancer (2011) NICE guideline CG131
-
Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (2010) NICE technology appraisal guidance 212
-
Capecitabine for the treatment of advanced gastric cancer (2010) NICE technology appraisal guidance 191
-
Cetuximab for the first-line treatment of metastatic colorectal cancer (2009) NICE technology appraisal guidance 176
-
Cetuximab for the treatment of head and neck cancer (2008) NICE technology appraisal guidance 145
-
Laparoscopic surgery for the treatment of colorectal cancer (2006) NICE technology appraisal guidance 105
-
Improving outcomes in head and neck cancers (2004) NICE cancer service guidance
-
Improving outcomes in colorectal cancer (2004) NICE cancer service guidance
-
Capecitabine and tegafur with uracil for metastatic colorectal cancer (2003) NICE technology appraisal guidance 61
Under development
NICE is developing the following guidance (details available from the NICE website):
-
Assessment and management of upper airways tract cancers. NICE guideline. Publication expected September 2015.